Sign up to watch this video
Free access to all Sound Bites content
Dr. Eytan Stein discusses durability of treatment in IC-ineligible AML (Video 1/3)
Published Sep 21, 2026
Medical Professional
AML durability of treatment
More in this series: IC-ineligible AML 2026
Related Videos
Dr. John Mascarenhas discusses how to recognize hydroxyurea resistance in essential thrombocythemia and when a treatment change may be appropriate (Video 1/3)
John Mascarenhas, MD
Dr. Rahul Banerjee reviews the safety profile of iberdomide and strategies for adverse event management (Video 3/3)
Rahul Banerjee, MD
Dr. Wade Iams describes an MDT approach to optimally care for patients with EGFRm mNSCLC on 1L amivantamab subQ + lazertinib (Video 3/3)
Wade Iams, MD
Dr. Rahul Banerjee highlights key findings with iberdomide, daratumumab, and dexamethasone in RRMM. (Video 2/3)
Rahul Banerjee, MD
Dr. Gabriela Hobbs discusses event-free survival outcomes with ropeginterferon in polycythemia vera (Video 3/3)
Gabriela Hobbs, MD
Dr. Eytan Stein explores how emerging clinical data and real-world experience are shaping the treatment landscape in AML (Video 3/3)
Eytan Stein, MD
IDEOlogy Health Ranks No. 772 on the 2025 Inc. 5000 Fastest-Growing Private Companies in America
© 2026 IDEOlogy Health. All product names, logos, brands, trademarks and registered trademarks are property of their respective owners and their use(s) do not necessarily imply endorsement.